The development of CRISPR/Cas9 based gene editing enables us to precisely alter the genome and thus correct disease-causing mutations. Correction of disease-causing variants in stem cells may enable the durable treatment of genetic diseases. The Vaidyanathan lab is pioneering the use of genome editing approaches to treat airway diseases including cystic fibrosis (CF). The immediate focus of the lab is the development of an engineered airway stem cell therapy to treat CF. Additional projects may include cell therapies targeting other airway diseases and the development of in vivo gene editing techniques.